Elite members get real-time data, technical charting, alerts, and no ads - starting at $24.96/mo. Try Elite Free for 7 Days

New feature: Automatically detect candlestick patterns on any chart

NervGen Pharma Corp.

Contributing Author

Recent Articles by NervGen Pharma Corp.

Aug-13	NervGen Reports Second Quarter 2026 Financial Results and Provides Business Updates NGEN GlobeNewswire
May-26	NervGen Announces Positive Independent, Blinded Biomechanical Gait Analyses Demonstrating Genuine Neural Recovery with NVG-291 in Phase 1b/2a CONNECT SCI Study NGEN GlobeNewswire
May-21	NervGen Announces Pricing of US$60.0 Million Public Offering of Securities NGEN -43.48% GlobeNewswire
May-21	NervGen Announces Proposed Public Offering of Securities NGEN NGEN -43.48% GlobeNewswire
May-18	NervGen Reports First Quarter 2026 Financial Results and Provides Business Updates NGEN GlobeNewswire
Apr-27	NervGen Pharma Strengthens Leadership Team with Appointment of Keith Vendola as Chief Financial Officer NGEN GlobeNewswire
Apr-13	NervGen Pharma to Participate in the H.C. Wainwright "HCW@Home" Series and the 2026 Bloom Burton & Co. Healthcare Investor Conference NGEN GlobeNewswire
Apr-07	NervGen Pharma Announces Successful End-of-Phase 2 Meeting and FDA Alignment on RESTORE, a Phase 3 Registrational Study of NVG-291 for Chronic Tetraplegia NGEN -9.57% GlobeNewswire
Mar-31	NervGen Pharma Reports Full Year 2025 Financial Results and Provides Business Updates NGEN GlobeNewswire
Mar-12	NervGen Pharma Announces Voluntary Delisting from TSX Venture Exchange NGEN NGEN -6.98% GlobeNewswire
Mar-04	NervGen Pharma Appoints Shamim Ruff as Chief Regulatory Affairs Officer and Christine McSherry as SVP, Patient Advocacy and Clinical Affairs NGEN +8.10% GlobeNewswire
Feb-18	NervGen Pharma to Participate at Upcoming Investor Conferences NGEN GlobeNewswire
Feb-12	NervGen Pharma Announces Retirement of Chief Financial Officer, Bill Adams NGEN GlobeNewswire
Feb-11	NervGen Pharma to Present at Unite2Fight Paralysis' 20th Annual Science and Advocacy Symposium NGEN GlobeNewswire
Feb-09	NervGen Pharma Appoints Adam Rogers as Chief Executive Officer to Continue Leading the Company's Growth and Execution of Its Mission in Spinal Cord Injury NGEN GlobeNewswire
Jan-20	NervGen Pharma to Ring the Nasdaq Closing Bell on January 22, 2026, Celebrating Its Recent Nasdaq Listing NGEN -6.93% GlobeNewswire
Jan-08	NervGen Pharma Begins Trading on Nasdaq Today NGEN GlobeNewswire

Affiliate • Advertise • Careers • Contact • Blog • Help • Privacy • Follow us on X • Do Not Sell My Personal Information

Stock quotes delayed by 1 minute. Futures and options delayed by 15 minutes.
Copyright © 2007-2026 Finviz.com. All Rights Reserved. Export All Screener Data (CSV)